Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
Patients in the study are treated with the combination of AFM24, Affimed’s innate cell engager (ICE®), and atezolizumab, Roche’s checkpoint inhibitor (CPI).
- Patients in the study are treated with the combination of AFM24, Affimed’s innate cell engager (ICE®), and atezolizumab, Roche’s checkpoint inhibitor (CPI).
- One patient showed a confirmed complete response, and three patients showed confirmed partial responses (PR).
- In addition, seven patients achieved stable disease, resulting in a disease control rate of 73.3% (11/15 patients).
- To access the call by phone, please use link: https://register.vevent.com/register/BIff607338e5d247f99b548240be2ad413 , and you will be provided with dial-in details and a pin number.